Preoperative treatment for ER + /HER2- breast cancer is evolving. Here, the authors present the results of the PREDIX LumB trial that showed no difference between using first either neoadjuvant paclitaxel chemotherapy or the CDK4/6 inhibitor palbociclib plus endocrine treatment, in terms of efficacy, and also describe the development of a predictive biomarker for neoadjuvant therapy response.
- Alexios Matikas
- Evangelos Tzoras
- Theodoros Foukakis
